🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› London
Clinical trial register · Canada

Clinical Trials in London, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Canada and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6540 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:55 UTC
6540
Studies in scope
all four open statuses
3515
Recruiting now
open to new participants
887
Lead sponsors
across recruiting studies
Top sites
Toronto 117 Montreal 107 Calgary 62 Vancouver 54 Edmonton 52
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's108 Western University, Canada39 AstraZeneca36 Novartis Pharmaceuticals24 Eli Lilly and Company23 Clear sponsor filter
Site location
Toronto117 Montreal107 Calgary62 Vancouver54 Edmonton52
All 74 locations
Target enrolment
to

Trials with a site in London

36 of 6540 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Canada
Start
Recruiting
A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)
NCT07624305Renal Insufficiency, Chronic
DrugsBalcinrenone/dapagliflozin·Dapagliflozin
AstraZeneca
Phase 3
2,800
Calgary, Edmonton, Winnipeg, Halifax, Brampton, Greater Sudbury, London, Mississauga
2026-09-01
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
DrugElecoglipron
AstraZeneca
Phase 3
6,950
Barrie, Etobicoke, Greater Sudbury, Hamilton, Kingston, London, Markham, Newmarket
2026-08-24
Recruiting
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
NCT07753993Chronic Kidney Disease
DrugElecoglipron
AstraZeneca
Phase 3
7,000
Calgary, Edmonton, Vancouver, Winnipeg, Saint John, London, Scarborough Village, Toronto
2026-08-21
Recruiting
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
NCT07720284High-risk Muscle Invasive Urothelial Carcinoma
DrugsRilvegostomig·Enfortumab Vedotin·Datopotamab deruxtecan·Opdivo
AstraZeneca
Phase 3
915
Calgary, Abbotsford British Columbia, Barrie, Hamilton, Kingston, London, Mississauga, Montreal
2026-07-16
Active, closed
A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM
NCT07608354Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
DrugsCliramitug·Eplontersen
AstraZeneca
Phase 2
326
Calgary, Vancouver, Halifax, London, Toronto, Montreal
2026-06-11
Recruiting
Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody
NCT07285213Clostridioides Difficile Infection
AstraZeneca
Phase 2
230
Edmonton, Vancouver, Victoria, Halifax, Hamilton, London, Montreal, Québec
2025-12-10
Recruiting
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT06952803Prostate Cancer
DrugsPrednisolone/Prednisone·Saruparib·Abiraterone
AstraZeneca
Phase 3
700
Calgary, Abbotsford British Columbia, Vancouver, Barrie, Brampton, London, Toronto, Chicoutimi
2025-08-06
Active, closed
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH
NCT07000136Heterozygous Familial Hypercholesterolaemia
DrugAZD0780
AstraZeneca
Phase 3
473
Vancouver, London, Chicoutimi, Montreal, Québec, Trois-Rivières
2025-06-10
Recruiting
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
NCT06960577Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate, Vinblastine
DrugsVinblastine·Methotrexate·Doxorubicin·Durvalumab
AstraZeneca
Phase 3
150
Hamilton, London, Ottawa, Montreal, Québec, Sherbrooke
2025-05-15
Recruiting
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
NCT06989112Endometrial Cancer
DrugsTaxotere·Rilvegostomig·Paraplatin·Taxol
AstraZeneca
Phase 3
600
Calgary, Edmonton, Winnipeg, Halifax, London, Toronto, Montreal, Québec
2025-03-27
Recruiting
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
NCT06742723Chronic Kidney Disease and Hypertension
DrugBaxdrostat/dapagliflozin
AstraZeneca
Phase 3
5,000
Edmonton, Surrey, Vancouver, Winnipeg, Saint John, Halifax, Etobicoke, London
2025-03-03
Recruiting
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
NCT06465810Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR
AstraZeneca
Observational
1,850
Vancouver, Halifax, London, Toronto, Montreal, Rimouski
2024-06-25
Recruiting
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
NCT06307652Heart Failure and Impaired Kidney Function
AstraZeneca
Phase 3
3,850
New Westminster, North Vancouver, Vancouver, Winnipeg, Sydney, Cambridge, Hamilton, London
2024-04-12
Recruiting
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
NCT06357533Non-Small Cell Lung Cancer
DrugsRilvegostomig·Datopotamab deruxtecan·Keytruda·Pembrolizumab
AstraZeneca
Phase 3
675
Vancouver, Winnipeg, St. John's, London, Newmarket, Oshawa, Toronto, Lévis
2024-04-11
Active, closed
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
NCT06268873Chronic Kidney Disease and Hypertension
DrugBaxdrostat/dapagliflozin
AstraZeneca
Phase 3
2,554
Edmonton, Vancouver, Winnipeg, Halifax, Sydney, Brampton, Concord, London
2024-03-29
Active, closed
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
NCT06346392Gastric Cancer, Gastroesophageal Junction Cancer
DrugsSonesitatug Vedotin·Ramucirumab·Trifluridine/Tipiracil·Apatinib
AstraZeneca
Phase 3
594
Barrie, London, North York, Ottawa, Toronto, Montreal
2024-03-04
Recruiting
Observational Study Protocol: LIVER-R
NCT06252753Hepatobiliary Cancers
AstraZeneca
Observational
4,000
Calgary, Edmonton, Halifax, London
2023-12-20
Recruiting
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
NCT06129864Locally Advanced Head and Neck Squamous Cell Carcinoma
DrugVolrustomig
AstraZeneca
Phase 3
1,145
Calgary, Edmonton, Kelowna, Kingston, London, Toronto, Chicoutimi, Montreal
2023-12-14
Active, closed
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
NCT06109779Biliary Tract Cancer
DrugsGemcitabine/Cisplatin·Rilvegostomig·Tegafur·Capecitabine
AstraZeneca
Phase 3
760
Vancouver, Halifax, Kingston, London, Ottawa, Toronto, Montreal, Québec
2023-12-04
Active, closed
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
NCT06112379Breast Cancer
DrugsDatopotamab deruxtecan·Epirubicin·Xeloda·Olaparib
AstraZeneca
Phase 3
1,902
Calgary, Vancouver, Barrie, London, Oshawa, Toronto, Lévis, Montreal
2023-11-14
Active, closed
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
NCT06087835Chronic Kidney Disease With High Proteinuria
DrugDapagliflozin
AstraZeneca
Phase 3
1,835
London, Waterloo, Greenfield Park, Montreal
2023-11-07
Recruiting
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
NCT06079671Locally Advanced Cervical Cancer
DrugVolrustomig
AstraZeneca
Phase 3
800
Hamilton, London, Toronto, Montreal, Ste-Foy
2023-09-22
Recruiting
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT05797168Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma
DrugsTorvutatug samrotecan·Palacaparib·Saruparib·Paraplatin
AstraZeneca
Phase 1/2
602
Edmonton, London, Toronto, Montreal
2023-06-05
Active, closed
Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis
NCT05583227Eosinophilic Esophagitis
DrugTezepelumab
AstraZeneca
Phase 3
368
Hamilton, London, Niagara Falls, Ottawa, Windsor
2022-11-10
Active, closed
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
NCT05221840Non-Small Cell Lung Cancer
DrugsMonalizumab·Oleclumab·Durvalumab
AstraZeneca
Phase 3
1,051
Edmonton, Barrie, Hamilton, Kingston, London, Mississauga, Toronto, Rimouski
2022-02-07
Recruiting
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
NCT04686305Locally Advanced or Metastatic Non-Small Cell Lung Cancer
DrugsVolrustomig·Rilvegostomig·Trastuzumab deruxtecan·Durvalumab
AstraZeneca
Phase 1
304
Winnipeg, London, Montreal
2021-03-09
Active, closed
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
NCT04711252ER-Positive HER2-Negative Breast Cancer
DrugsCamizestrant·Anastrozole·Palbociclib
AstraZeneca
Phase 3
1,370
Edmonton, Vancouver, Kitchener, London, Toronto, Montreal
2021-01-28
Active, closed
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
NCT04494425Advanced or Metastatic Breast Cancer
DrugsTrastuzumab deruxtecan·Nab-paclitaxel·Capecitabine·Paclitaxel
AstraZeneca
Phase 3
866
Calgary, Edmonton, Vancouver, Toronto, London, Montreal, Sherbrooke
2020-07-24
Active, closed
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
NCT03833154Carcinoma, Non-Small-Cell Lung
DrugDurvalumab
AstraZeneca
Phase 3
724
Edmonton, London, Toronto, Montreal
2019-03-06
Active, closed
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
NCT03742102Triple Negative Breast Neoplasms
DrugsOleclumab·Capivasertib·Datopotamab deruxtecan·Trastuzumab deruxtecan
AstraZeneca
Phase 1/2
243
Kelowna, London, Greenfield Park, Montreal
2018-12-21
Active, closed
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
NCT03732677Muscle Invasive Bladder Cancer
DrugsDurvalumab·Gemcitabine·Cisplatin
AstraZeneca
Phase 3
1,063
Edmonton, Vancouver, London, Ottawa, Toronto, Montreal, Sherbrooke
2018-11-16
Active, closed
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
NCT03732820Metastatic Castration-resistant Prostate Cancer
DrugsAbiraterone acetate·Olaparib
AstraZeneca
Phase 3
895
Calgary, Edmonton, Kelowna, Halifax, London, Toronto, Greenfield Park, Montreal
2018-10-31
Active, closed
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
NCT03703297Small Cell Lung Cancer
DrugsTremelimumab·Durvalumab
AstraZeneca
Phase 3
730
Edmonton, Toronto, Winnipeg, Hamilton, London, Ottawa, Montreal
2018-09-27
Active, closed
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
NCT03298451Hepatocellular Carcinoma
DrugsSorafenib·Tremelimumab·Durvalumab
AstraZeneca
Phase 3
1,324
Calgary, Edmonton, Hamilton, Kingston, London, Toronto, Montreal, Québec
2017-10-11
Active, closed
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT01874353Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
DrugOlaparib
AstraZeneca
Phase 3
327
Hamilton, London, Toronto, Montreal, Québec, Sherbrooke
2013-09-03
Active, closed
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
NCT01844986Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation
DrugOlaparib
AstraZeneca
Phase 3
450
Hamilton, London, Toronto, Montreal, Québec
2013-08-26
Rows per page Showing 1–36 of 36
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Canadian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-canada/city/london

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Canada and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,540 studies in total at the last sync on 26 Sep 2026, 19:55 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 36 of those studies with a site in London that also match the filters currently applied.

How many clinical trials are recruiting in London?

17 of the 36 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:55 UTC sync. A further 0 have not yet opened recruitment, 19 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (London), 36 studies
PhaseStudiesRecruitingShare
Phase 3291280.6%
Observational225.6%
Phase 1/2215.6%
Phase 2215.6%
Phase 1112.8%

Most active sponsors

Lead sponsors with the most studies (London)
Lead sponsorStudiesRecruiting
AstraZeneca3617
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.